EUVIMEDEUVIMED entdecken
Crossref

Feasibility and Safety of Aerosolized Influenza Virus Challenge in Humans Using Two Modern Delivery Systems

Nadine Rouphael iD, Ralph Tanios, Jessica Traenkner, Matthew D Pauly iD, Nishit Shetty iD, Meredith J Shephard, A J Campbell iD, Christelle Radi, Shamika Danzy, Jin Pan iD, Andrew P Catchpole, Alex Mann und 5 weitere

The Journal of Infectious Diseases · 15.05.2026 · 233 (5) · 858-867

DOI: 10.1093/infdis/jiaf603 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 16.12.2025. Verfasst von Nadine Rouphael und 16 weiteren Autor:innen. Beteiligte Einrichtung: Hope Clinic, Division of Infectious Diseases, Department of Medicine, Emory University, Decatur, Georgia, USA. Hauptthemen laut MEDLINE: Influenza, Human, Influenza A Virus, H3N2 Subtype. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Flu Lab.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Controlled human infection models are widely used to study infectious diseases. Since the 1960s, these studies have primarily relied on intranasal inoculation, as earlier aerosol-based methods raised safety concerns and were largely abandoned despite better mimicking the natural route of infection.

Methods

Utilizing modern advances in aerosol delivery, we conducted a dose-escalation study to evaluate the safety and feasibility of aerosol inoculation for human influenza challenge. Healthy adults aged 18–49 years were inoculated with influenza A/Perth/16/2009 (H3N2) using either a flow-focusing monodisperse aerosol generator (FMAG) delivering coarse particles or a medical nebulizer delivering fine particles. Participants were monitored in a controlled inpatient setting with symptom tracking, virologic sampling, and serology. Doses were escalated according to predefined safety and attack rate thresholds.

Results

Fourteen participants were enrolled. Flow-focusing monodisperse aerosol generator delivery at higher dose levels resulted in infection in 75% of participants (3/4), while nebulizer delivery produced infection in 50% (2/4). Illnesses were mild and self-limited. Viral shedding was detected at multiple respiratory sites, and adverse events were infrequent and generally mild. No serious adverse events occurred. Antibody responses were observed in a subset of infected participants.

Conclusions

In this small pilot, aerosolized challenge using modern delivery systems was feasible under controlled conditions; no safety concerns were identified, and MMID was induced in a subset of participants. These data establish a methodological framework for future studies evaluating pathogenesis and mucosal immune responses to a variety of respiratory pathogens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza, HumanInfluenza A Virus, H3N2 SubtypeHumansAdultMiddle AgedFemaleAerosolsMaleYoung AdultAdolescentFeasibility StudiesAdministration, InhalationNebulizers and VaporizersAntibodies, Viral

Stichwörter der Autor:innen

aerosol inoculationcontrolled human infection modelflow-focusing monodisperse aerosol generatorinfluenza A (H3N2)nebulizer

Substanzen

AerosolsAntibodies, Viral

Autor:innen und Institutionen

  • Hope Clinic, Division of Infectious Diseases, Department of Medicine, Emory University, Decatur, Georgia, USA.
  • Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Department of Civil, Environmental and Architectural Engineering, University of Kansas; Lawrence, Kansas, USA.
  • Department of Occupational and Environmental Health, College of Public Health, University of Iowa; Iowa City, Iowa, USA.
  • hVIVO, London, United Kingdom.
  • Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, Emory University; Atlanta, Georgia, USA.

ORCID-Profile: Nadine Rouphael, Matthew D Pauly, Nishit Shetty, A J Campbell, Jin Pan, Linsey C Marr, Seema S Lakdawala

Förderung

  • Flu Lab

Zitieren

APA

Rouphael, N., Tanios, R., Traenkner, J., Pauly, M. D., Shetty, N., Shephard, M. J., Campbell, A. J., Radi, C., Danzy, S., Pan, J., Catchpole, A. P., Mann, A., Detelich, J. F., Lowen, A. C., Marr, L. C., Lakdawala, S. S., & Flu CHIM Study Group (2026). Feasibility and Safety of Aerosolized Influenza Virus Challenge in Humans Using Two Modern Delivery Systems. The Journal of Infectious Diseases, 233(5), 858-867. https://doi.org/10.1093/infdis/jiaf603

Vancouver

Rouphael N, Tanios R, Traenkner J, Pauly MD, Shetty N, Shephard MJ, et al. Feasibility and Safety of Aerosolized Influenza Virus Challenge in Humans Using Two Modern Delivery Systems. The Journal of Infectious Diseases. 2026;233(5):858-867. doi:10.1093/infdis/jiaf603

BibTeX
@article{Rouphael2026,
  author = {Rouphael, Nadine and Tanios, Ralph and Traenkner, Jessica and Pauly, Matthew D and Shetty, Nishit and Shephard, Meredith J and Campbell, A J and Radi, Christelle and Danzy, Shamika and Pan, Jin and Catchpole, Andrew P and Mann, Alex and Detelich, Joshua F and Lowen, Anice C and Marr, Linsey C and Lakdawala, Seema S and Flu CHIM Study Group, Flu CHIM Study Group},
  title = {Feasibility and Safety of Aerosolized Influenza Virus Challenge in Humans Using Two Modern Delivery Systems},
  journal = {The Journal of Infectious Diseases},
  year = {2026},
  volume = {233},
  number = {5},
  pages = {858--867},
  doi = {10.1093/infdis/jiaf603}
}
Kostenlos starten →